Related Experiment Video
Updated: Mar 13, 2026
08:32
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
10.5K
Exploring the intrinsic differences among breast tumor subtypes defined using immunohistochemistry markers based on
Yang Li1, Xu-Qing Tang1, Zhonghu Bai2,3
1School of Science, Jiangnan University, Wuxi 214122, China.
Scientific Reports
|October 28, 2016
Summary
This study reveals distinct molecular differences in breast cancer subtypes using gene expression. A new 30-mRNA signature aids in precise breast tumor subtyping and understanding heterogeneity for clinical applications.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Breast cancer exhibits significant heterogeneity, complicating diagnosis and treatment.
- Current subtype classification using immunohistochemistry (IHC) and gene expression can be inconsistent.
Purpose of the Study:
- To explore intrinsic molecular differences among IHC-defined breast cancer subtypes.
- To develop a novel gene expression signature for improved breast tumor subtyping.
Main Methods:
- Utilized a decision tree approach to analyze subtypes defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
- Identified differentially expressed messenger RNAs (mRNAs) and microRNAs (miRNAs).
- Validated a 30-mRNA signature using public datasets and established classifiers; performed network and pathway analysis.
Main Results:
- Identified 30 mRNAs and 7 miRNAs with differential expression across decision tree branches.
- The 30-mRNA signature demonstrated robust performance in validation datasets.
- Network analysis highlighted key molecules like FOXQ1 and SFRP1 involved in metabolic pathways.
Conclusions:
- Uncovered distinct mRNA and miRNA expression differences among the four IHC-defined breast tumor subtypes.
- Presented a novel mRNA signature for precise breast tumor subtyping.
- Identified potential key molecules driving breast tumor heterogeneity, offering clinical insights.
